Neutra Corp. (NTRR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -233.46 Thousand USD | 58.42% |
| 2023 | -561.41 Thousand USD | 100.0% |
| 2022 | -127.44 Billion USD | -19294062.97% |
| 2021 | -660.54 Thousand USD | 36.26% |
| 2020 | -1.03 Million USD | 57.34% |
| 2019 | -2.42 Million USD | -368.08% |
| 2018 | -519.03 Thousand USD | 40.2% |
| 2017 | -867.88 Thousand USD | -160.16% |
| 2016 | 1.44 Million USD | 176.06% |
| 2015 | -1.89 Million USD | -50.75% |
| 2014 | -1.25 Million USD | -244.02% |
| 2013 | -365.75 Thousand USD | -350.35% |
| 2012 | -81.21 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -54.98 Thousand USD | 23.47% |
| 2024 Q1 | -71.99 Thousand USD | 73.82% |
| 2024 Q4 | -34.63 Thousand USD | 37.01% |
| 2024 FY | -233.46 Thousand USD | 58.42% |
| 2024 Q2 | -71.84 Thousand USD | 0.21% |
| 2023 Q2 | -97.42 Thousand USD | 20.75% |
| 2023 FY | -561.41 Thousand USD | 100.0% |
| 2023 Q3 | -81.79 Thousand USD | 16.05% |
| 2023 Q1 | -122.93 Thousand USD | 100.0% |
| 2023 Q4 | -275 Thousand USD | -236.22% |
| 2022 Q1 | -137.31 Thousand USD | 44.38% |
| 2022 Q4 | -127.44 Billion USD | -71216622.0% |
| 2022 Q2 | -140.88 Thousand USD | -2.6% |
| 2022 FY | -127.44 Billion USD | -19294062.97% |
| 2022 Q3 | -178.95 Thousand USD | -27.02% |
| 2021 Q3 | -109.32 Thousand USD | -51.2% |
| 2021 Q4 | -246.89 Thousand USD | -125.84% |
| 2021 Q2 | -72.3 Thousand USD | 34.49% |
| 2021 FY | -660.54 Thousand USD | 36.26% |
| 2021 Q1 | -110.37 Thousand USD | 47.58% |
| 2020 FY | -1.03 Million USD | 57.34% |
| 2020 Q4 | -210.55 Thousand USD | 3.88% |
| 2020 Q1 | -128.21 Thousand USD | 71.23% |
| 2020 Q2 | -137.79 Thousand USD | -7.48% |
| 2020 Q3 | -219.05 Thousand USD | -58.97% |
| 2019 Q1 | -131.84 Thousand USD | -31.24% |
| 2019 FY | -2.42 Million USD | -368.08% |
| 2019 Q4 | -445.71 Thousand USD | 73.99% |
| 2019 Q3 | -1.71 Million USD | -1137.43% |
| 2019 Q2 | -138.46 Thousand USD | -5.02% |
| 2018 Q4 | -100.45 Thousand USD | -84.56% |
| 2018 Q3 | -54.43 Thousand USD | 64.68% |
| 2018 FY | -519.03 Thousand USD | 40.2% |
| 2018 Q1 | -210.01 Thousand USD | 40.56% |
| 2018 Q2 | -154.12 Thousand USD | 26.61% |
| 2017 Q1 | -183.33 Thousand USD | -108.19% |
| 2017 Q2 | -164.91 Thousand USD | 10.05% |
| 2017 Q3 | -166.29 Thousand USD | -0.84% |
| 2017 FY | -867.88 Thousand USD | -160.16% |
| 2017 Q4 | -353.32 Thousand USD | -112.47% |
| 2016 Q2 | -195.32 Thousand USD | 45.61% |
| 2016 FY | 1.44 Million USD | 176.06% |
| 2016 Q1 | -359.1 Thousand USD | 24.67% |
| 2016 Q4 | 2.23 Million USD | 1030.42% |
| 2016 Q3 | -240.48 Thousand USD | -23.12% |
| 2015 Q3 | -531.83 Thousand USD | -0.73% |
| 2015 Q2 | -527.97 Thousand USD | -46.54% |
| 2015 Q1 | -360.3 Thousand USD | 12.68% |
| 2015 FY | -1.89 Million USD | -50.75% |
| 2015 Q4 | -476.69 Thousand USD | 10.37% |
| 2014 Q2 | -274.95 Thousand USD | -25.59% |
| 2014 FY | -1.25 Million USD | -244.02% |
| 2014 Q3 | -349.76 Thousand USD | -27.21% |
| 2014 Q1 | -218.93 Thousand USD | -161.54% |
| 2014 Q4 | -412.62 Thousand USD | -17.97% |
| 2013 Q2 | -102.87 Thousand USD | -26.84% |
| 2013 Q3 | -98.07 Thousand USD | 4.66% |
| 2013 Q4 | -83.7 Thousand USD | 14.65% |
| 2013 FY | -365.75 Thousand USD | -350.35% |
| 2013 Q1 | -81.09 Thousand USD | -36.32% |
| 2012 Q2 | -17.38 Thousand USD | -2977.35% |
| 2012 FY | -81.21 Thousand USD | 0.0% |
| 2012 Q1 | -565.00 USD | 0.0% |
| 2012 Q4 | -59.49 Thousand USD | -1477.2% |
| 2012 Q3 | -3772.00 USD | 78.31% |
| 2011 FY | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 82.518% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 96.657% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.441% |
| Nascent Biotech, Inc. | -2.08 Million USD | 88.817% |
| Rebus Holdings, Inc. | -1.02 Million USD | 77.111% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.358% |
| Qrons Inc. | -789.34 Thousand USD | 70.423% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 63.083% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.627% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 43.808% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.38% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.689% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 96.45% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 14.607% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.706% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 91.928% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 87.176% |
| Mesoblast Limited | -87.95 Million USD | 99.735% |
| Marizyme, Inc. | -65.34 Million USD | 99.643% |
| Genus plc | 7.9 Million USD | 102.955% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 97.856% |
| Pharming Group N.V. | -10.54 Million USD | 97.787% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 89.24% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 93.708% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 97.36% |
| ContraFect Corporation | -65.15 Million USD | 99.642% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 95.222% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 86.485% |
| IMV Inc. | -36.48 Million USD | 99.36% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 97.103% |
| MultiCell Technologies, Inc. | -380.07 USD | -61326.842% |
| ONE Bio Corp. | 8.67 Million USD | 102.691% |
| Accustem Sciences Inc. | -3.74 Million USD | 93.768% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.548% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 81.575% |
| Q BioMed Inc. | -2.05 Million USD | 88.623% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 93.746% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 90.194% |
| Biomind Labs Inc. | -1.21 Million USD | 80.774% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.609% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 92.473% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 97.046% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 88.023% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -1458.928% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 98.529% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 95.987% |
| GB Sciences, Inc. | -1.36 Million USD | 82.855% |
| Alpha Cognition Inc. | -13.77 Million USD | 98.305% |
| HST Global, Inc. | -146.21 Thousand USD | -59.678% |
| CSL Limited | 2.64 Billion USD | 100.009% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 86.695% |
| Halberd Corporation | -79.67 Thousand USD | -193.018% |
| Enzolytics Inc. | -2.17 Million USD | 89.275% |
| Agentix Corp. | -1.37 Million USD | 83.011% |
| Resverlogix Corp. | -3.61 Million USD | 93.533% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 92.639% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.921% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 338.23% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 103.372% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 94.124% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 92.285% |
| AVAX Technologies, Inc. | -6.41 Million USD | 96.36% |
| Zenith Capital Corp. | -10.59 Million USD | 97.797% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.755% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -904.496% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 94.369% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -286.272% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 88.357% |
| Kadimastem Ltd | -3.3 Million USD | 92.941% |
| Helix BioMedix, Inc. | -1.05 Million USD | 77.893% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 93.887% |
| BioStem Technologies, Inc. | -8.48 Million USD | 97.248% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 47.104% |
| LadRx Corporation | 400.44 Thousand USD | 158.302% |
| Cell Source, Inc. | -5.32 Million USD | 95.613% |
| Regen BioPharma, Inc. | 1.02 Million USD | 122.81% |
| Regen BioPharma, Inc. | 1.02 Million USD | 122.81% |
| NovAccess Global Inc. | -4.76 Million USD | 95.105% |
| Affymax, Inc. | -14.42 Million USD | 98.381% |
| Itoco Inc. | -1.86 Million USD | 87.509% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 94.745% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 86.012% |
| Mobile Lads Corp. | -2.26 Million USD | 89.685% |
| CytoDyn Inc. | -49.84 Million USD | 99.532% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -195.402% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2.34% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 75.204% |
| SYBLEU INC | -180.3 Thousand USD | -29.484% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 85.524% |
| International Stem Cell Corporation | -131 Thousand USD | -78.218% |
| Bioxytran, Inc. | -4.28 Million USD | 94.545% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -330.176% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 90.773% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.514% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 88.956% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 70.103% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 92.631% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 98.849% |
| PureTech Health plc | -65.69 Million USD | 99.645% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 98.902% |
| IXICO plc | -1.17 Million USD | 80.181% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 97.648% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.591% |
| CSL Limited | 2.64 Billion USD | 100.009% |
| Cellectis S.A. | -103.17 Million USD | 99.774% |